article thumbnail

DEBRA Research, LEO Pharma Partner to Advance Treatments for EB

The Dermatology Digest

We are pleased to announce our non-exclusive partnership with LEO Pharma, which has demonstrated a strong track record in developing medicines for hard-to-treat skin conditions, saysProf.Hubert Truebel, MD, MBA, Managing Director at DEBRA Research, in a news release. There are currently no approved treatment options for EB.

article thumbnail

New Tox in Town: LetibotulinumtoxinA-wlbg (Letybo, Hugel & Benev) Now Fully Commercialized in the U.S.

The Dermatology Digest

market,” says Ethan Min, Chief Executive Officer at BENEV, in a news release. “This partnership with Hugel allows us to strengthen our market position and fulfill our mission to BENefit EVeryone through transformative aesthetic solutions.” “We are honored to join forces with Hugel to bring Letybo to the U.S.

article thumbnail

L’Oreal to Buy 10% Stake in Galderma

The Dermatology Digest

The two companies are also teaming up for a new a scientific partnership focused on complementary research projects. “We We look forward to pursuing scientific partnership opportunities together, for the benefit of the customers, patients and consumers we serve across the globe every day.” “I

article thumbnail

7 Ways We’re An Eco-Friendly Business 

Eminence Organics

From our green office space in Vancouver, Canada to our sustainable farming practices in Hungary, being green is at the heart of what we do. Eminence Organics, in partnership with Trees For The Future , plants a tree for every retail skin care product sold, allowing us to support communities in developing countries.

Office 105
article thumbnail

Done Deal: Organon Completes Acquisition of Dermavant

The Dermatology Digest

“The future of dermatology depends on innovative treatments like VTAMA, and Organon’s acquisition of Dermavant allows us to further expand our existing portfolio of established brands and biosimilar dermatology treatments,” says Kevin Ali, Chief Executive Officer of Organon, in a news release.

article thumbnail

U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN

The Dermatology Digest

This FDA approval shows the power of collaboration to advance innovative science for drugs that may otherwise not have been taken forward, says Annette Bakker, PhD, Chief Executive Officer of the Childrens Tumor Foundation. Every treatment approval is hard-won, built on research, persistence, and partnership.

article thumbnail

Touchdown: Novartis Named First-ever Corporate Pharmaceutical Partner of the NFL

The Dermatology Digest

The partnership aims to empower football fans everywhere to make proactive decisions about their health, better understand screening guidelines and create a playbook for a healthier future. Novartis is the official first-in-category corporate pharmaceutical partner of the National Football League (NFL).